Daiwa Securities Group Inc. Boosts Holdings in Amgen Inc. $AMGN

Daiwa Securities Group Inc. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 238,742 shares of the medical research company’s stock after acquiring an additional 3,249 shares during the period. Daiwa Securities Group Inc.’s holdings in Amgen were worth $78,143,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of AMGN. Norges Bank purchased a new stake in shares of Amgen during the 4th quarter worth about $2,164,162,000. Capital World Investors grew its holdings in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Geode Capital Management LLC boosted its holdings in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the period. Finally, National Bank of Canada FI boosted its holdings in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission approval for Imdelltra, a regulatory win that could expand its cancer-treatment revenue opportunity in Europe. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen said it will present new data across rare autoimmune and inflammatory diseases at EULAR 2026, with updates supporting UPLIZNA and TAVNEOS, which may reinforce confidence in its specialty-drug growth. Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026
• Positive Sentiment: Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference, which could keep investor focus on its strategy and pipeline progress. Amgen to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Amgen’s appearance at the Jefferies Global Healthcare Conference is keeping the stock in the spotlight, but the transcript itself does not add a clear new catalyst. Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Amgen is also getting some broader attention from commentary on AI adoption in biotech and analyst notes on healthcare names, but these items appear more informational than stock-moving. The CEO who loves AI autodidacts — and desperately needs his experts Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Analysts Set New Price Targets

AMGN has been the subject of a number of analyst reports. Wells Fargo & Company upped their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Morgan Stanley set a $332.00 price target on Amgen in a report on Friday, May 1st. Canaccord Genuity Group initiated coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target for the company. Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Finally, Jefferies Financial Group initiated coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $355.19.

Amgen Stock Performance

Shares of AMGN opened at $345.60 on Friday. The business’s 50 day moving average is $341.44 and its two-hundred day moving average is $345.44. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The firm has a market cap of $186.52 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 3.39 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company posted $4.90 EPS. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.